What’s funding like in the Longevity Biotech market right now?

All funding deals in the Longevity Biotech Market over the last 24 months

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the Longevity Biotech Market.

Is Longevity Biotech funding actually healthier now?

Longevity Biotech funding is healthier today for companies that have already proved something, but the market is not healthier across the board.

We counted 18 financings in the latest 12 months, up from 14, while disclosed capital more than doubled from $376.5 million to $775.3 million. At first glance, that looks like a boom. The rest of the data tells a more uneven story. Only 15 companies raised money, versus 14 previously, and the median disclosed round fell from $16 million to $12 million.

The big improvement sits at the top. NewLimit raised $435 million, Loyal raised $100 million, and Life Biosciences raised $80 million. Together, those three rounds absorbed almost four-fifths of all disclosed capital.

Meanwhile, fewer newly funded companies entered the market and most current transactions were follow-ons. We are looking at a market that has become very good at financing a handful of companies moving into expensive development programs, while the wider startup pipeline has not strengthened nearly as much.

Metric	Current L12M	Previous 12M	Change
Deals	18	14	+28.6%
Unique companies	15	14	+7.1%
Disclosed capital	$775.3M	$376.5M	+105.9%
Median disclosed round	$12.0M	$16.0M	-25.0%
Average disclosed round	$51.7M	$29.0M	+78.5%
Reliable first-financing share	11.8%	35.7%	-23.9 pp
Follow-on share	88.2%	64.3%	+23.9 pp
Largest deal / disclosed capital	56.1%	34.5%	+21.6 pp

Would Longevity Biotech still look stronger without the giant rounds?

Longevity Biotech would look roughly flat to slightly weaker today if we removed the biggest rounds.

Headline disclosed funding increased by 105.9%. Once we exclude rounds above $50 million, current-period capital falls to $160.3 million, compared with $170.5 million previously. That is a 6% decline.

Even the monthly pattern points in the same direction. Average monthly disclosed funding more than doubled because one exceptionally large month pulled the figure upward. Median monthly capital barely moved, from around $20.8 million to $22.4 million.

There is still some genuine improvement below NewLimit. Excluding only rounds above $100 million leaves current funding 38% higher. But the ordinary funding environment did not experience anything close to a doubling.

The useful way to read the market now is that large winners can raise much more money than they could a year earlier. For most other companies, funding conditions look far less transformed.

Is NewLimit basically carrying the Longevity Biotech funding boom?

NewLimit is carrying more than half of current Longevity Biotech funding, so any market-level conclusion has to start there.

Its $435 million Series C represents 56.1% of all disclosed capital in the latest period. Remove that single transaction and current disclosed funding falls to roughly $340 million, below the previous period's $376.5 million.

NewLimit also raised $45 million earlier in the current window, only five months after its $130 million Series B. We therefore have one company contributing two transactions and $480 million of current-period capital.

That concentration does reflect real progress. In its financing announcement, NewLimit said it was preparing its first aging-reprogramming medicine for human trials after identifying a prototype medicine and scaling manufacturing. These days, investors are writing very large checks when a longevity platform starts looking like an actual drug-development company.

Still, the headline "Longevity Biotech funding doubled" becomes very hard to defend once NewLimit is taken out of the picture.

Are more Longevity Biotech companies getting funded now?

Only slightly more Longevity Biotech companies are getting funded today, even though there are quite a few more financing events.

Deal count rose from 14 to 18, but unique funded companies increased from 14 to 15. Most of the extra transactions therefore came from companies raising again.

NewLimit raised twice during the current period. HexemBio also recorded two financings. EonArk announced a Seed followed shortly afterwards by a Seed+ round. There were no multiple-financing companies in the previous period.

That distinction is easy to miss when looking at deal count alone. We have more fundraising activity, but not a much larger population of funded Longevity Biotech companies.

Are investors still funding new Longevity Biotech startups?

New Longevity Biotech startups are having a much harder time capturing funding than the headline market numbers suggest.

Reliable first financings fell from five in the previous period to two in the current one, plus TECregen as an uncertain case because investors had apparently backed the company before its recorded seed completion. On an audited basis, first financings dropped from 35.7% of deals to roughly 11.8%.

The dollar gap is even wider. Reliable first financings currently account for $5.5 million of disclosed capital plus an undisclosed EonArk round. In the previous period, new entrants attracted around $76.2 million of disclosed financing.

General Control's $5.5 million seed and EonArk's first institutional round show that company formation has not stopped. But new startups are nowhere near the center of the market now. Investors are putting most of their money behind companies that have already survived at least one earlier financing cycle.

Indicator	Current	Previous
Reliable first financings	2 + 1 uncertain	5
Reliable first-financing share	11.8%	35.7%
Follow-ons	15	9
Follow-on share	88.2%	64.3%
Disclosed capital in reliable first financings	$5.5M + undisclosed	$76.2M
Follow-on disclosed capital	$757.2M	$300.3M
Median disclosed first financing	$5.5M	$15.6M
Median disclosed follow-on	$12.0M	$16.0M

Why are existing Longevity Biotech companies getting so much more money?

Existing Longevity Biotech companies are getting more money because several of them have reached stages where clinical work, manufacturing, regulation and commercialization require much larger budgets.

NewLimit is preparing for human trials. Life Biosciences raised $80 million to fund its Phase 1 ER-100 trial and the rest of its partial epigenetic reprogramming pipeline. Loyal raised $100 million to move LOY-002 toward FDA approval. Juvena Therapeutics raised $33.5 million to advance regenerative biologics.

These companies are considerably further along than a typical discovery-stage startup raising a seed round. A few years of scientific work can turn a relatively capital-light platform company into a biotech that needs tens or hundreds of millions of dollars to run regulated development programs.

That helps explain why current funding looks so strong without requiring us to believe investors suddenly became enthusiastic about every longevity startup.

Are Longevity Biotech rounds getting bigger now?

The typical Longevity Biotech round is actually smaller now.

The median disclosed financing fell 25%, from $16 million to $12 million, while the average jumped from $29 million to $51.7 million. A handful of huge rounds are pulling the average upward.

At the smaller end, ARTAN Bio raised $1 million, HexemBio later recorded a $2 million investment, General Control raised $5.5 million, Rejuvenate Bio raised $6 million, and Junevity added another $10 million to its seed financing. Those transactions sit in the same market as Loyal's $100 million and NewLimit's $435 million rounds.

Funding has become much more uneven. A growing number of companies are raising relatively modest amounts while a small mature group can now raise at a scale that barely existed in the previous period.

Is the middle of the Longevity Biotech funding market getting squeezed?

Yes, the middle of the Longevity Biotech market looks noticeably thinner right now.

Deals between $20 million and $50 million fell from 28.6% of transactions to 11.1%. At the same time, nine current deals are classified as seed while $100 million-plus rounds account for 69% of disclosed capital.

The previous period had several companies in that middle range, including Immunis at $25 million and Jocasta Neuroscience at $35 million. In the current period, Juvena Therapeutics at $33.5 million is one of the relatively few obvious examples.

Series A is another warning sign. We recorded four Series A deals previously and none in the latest period. Four current deals have unknown stages, so we should not overstate that zero, but the broader shape is difficult to miss.

There is still money for small seed rounds and plenty of money for a few mature winners. The $20 million to $50 million layer has become much quieter.

Deal-size bucket	Current deal share	Current capital share	Previous deal share	Previous capital share
<$5M	11.1%	0.4%	0%	0%
$5M–<$20M	44.4%	10.2%	50.0%	18.1%
$20M–<$50M	11.1%	10.1%	28.6%	27.1%
$50M–<$100M	5.6%	10.3%	7.1%	20.2%
$100M+	11.1%	69.0%	7.1%	34.5%
Top three deals	-	79.3%	-	64.0%
Top five deals	-	89.5%	-	76.5%

Has Longevity Biotech funding moved toward later-stage companies?

Longevity Biotech dollars have moved sharply toward later-stage companies, even though seed deals still make up half of current activity.

Later-stage transactions account for only 27.8% of deals but absorb 84.4% of disclosed capital. A year earlier, they represented 60.6% of capital.

NewLimit's Series C, Loyal's Series C and Life Biosciences' Series D explain much of the shift. Those three rounds alone total $615 million.

Seed activity has not disappeared: we counted nine seed deals, up from seven. What has changed is how little capital those rounds command relative to the rest of the market. Seed financings represent half of current deals but only 6.6% of disclosed dollars.

As seen above, this is one reason the market can look active at the bottom and extremely strong at the top while still feeling thin in between.

Is cellular reprogramming really taking over Longevity Biotech funding?

Cellular reprogramming is currently the clear center of gravity in Longevity Biotech funding.

The category generated five current-period financings and around $570 million of disclosed capital. Its share of market dollars rose from roughly 41% to 74%.

NewLimit dominates that figure, but there is more going on than one company. Life Biosciences raised $80 million for its partial epigenetic reprogramming platform, and Junevity expanded its seed financing to $20 million in total to advance siRNA-based cellular reprogramming.

The important difference is that reprogramming has gained both activity and capital. Some other categories gained one without the other. Stem-cell and regenerative therapies doubled their deal count from two to four, for example, but their rounds remained much smaller. Metabolic and mitochondrial therapies raised more money largely because Loyal alone secured $100 million.

Cellular reprogramming therefore has the strongest momentum in the market today, although a large part of its dollar dominance still rests on NewLimit.

Why are investors putting so much money into cellular reprogramming now?

Investors are putting more money into cellular reprogramming because the leading companies are beginning to move beyond platform research and into human drug development.

NewLimit says its first reprogramming medicine is being prepared for human clinical trials, backed by manufacturing scale-up and a prototype medicine that reversed cellular age in old human liver cells. Life Biosciences has already moved ER-100 into Phase 1 and announced the first patient dosing during the current funding period.

Junevity remains earlier, but its latest financing is also aimed at taking JUN_01 toward first-in-human studies.

Those are expensive transitions. Manufacturing, toxicology, regulatory work, clinical operations and expanded development teams cost far more than running an early research platform.

The latest financing wave lines up with a real change in what some reprogramming companies are trying to do. The field is starting to test whether years of rejuvenation biology can produce regulated medicines in humans.

Which other parts of Longevity Biotech are gaining momentum?

Regenerative therapies are gaining activity, while metabolic longevity is attracting bigger checks through a much narrower group of companies.

Stem-cell and regenerative therapies went from two financings to four. Juvena raised $33.5 million, TECregen completed a $12.6 million seed, and HexemBio raised $10.4 million before recording another investment later in the period. That gives the category more company-level activity, even though it remains far behind cellular reprogramming in dollars.

Metabolic and mitochondrial therapies had only two current deals, but Loyal's $100 million round pushed category funding above $100 million. That is strong capital momentum with very little breadth.

Longevity discovery platforms moved the other way. Disclosed capital fell from around $90.9 million to $17 million, although EonArk raised two undisclosed rounds, so the true decline is smaller than the disclosed figures imply.

Category	Current deals	Current disclosed capital	Previous deals	Previous disclosed capital
Cellular Reprogramming	5	$570M	3	$156M
Stem Cell & Regenerative	4	$58.5M	2	$45.2M
Longevity Discovery Platforms	3	$17M + undisclosed	4	$90.9M
Metabolic & Mitochondrial	2	$105.3M	3	$63.4M
Gene & Telomere	2	$7M	2	$21M
Epigenetic Therapies	1	$5.5M	0	-
Autophagy & Proteostasis	1	$12M	0	-

Are successful Longevity Biotech companies raising again faster?

The Longevity Biotech companies that investors like are coming back for money much faster now.

Among follow-ons where we could reliably recover the previous financing, the median gap fell from 11.2 months to 6.4 months. All six usable current-period transactions occurred within 12 months of the company's previous round.

NewLimit provides the clearest sequence: $130 million in May 2025, another $45 million five months later, and $435 million roughly eight months after that. HexemBio raised $10.4 million and then recorded another investment within the same year. EonArk moved from Seed to Seed+ within weeks.

The sample is small, so we would not claim that every Longevity Biotech company can now raise twice as fast. For the companies already attracting investor conviction, however, fundraising cycles have clearly shortened.

Are Longevity Biotech investors becoming less picky?

Longevity Biotech investors look more selective these days, despite the rise in total funding.

The biggest checks are clustering around companies with much more evidence behind them. NewLimit has manufacturing progress and a route toward human trials. Loyal is working through FDA approval. Life Biosciences has entered Phase 1. Rejuvenate Bio paired its financing with a Merck Animal Health R&D collaboration.

At the same time, new-company financings have become scarcer, the median round is smaller and disclosed lead-investor breadth did not expand alongside deal count.

Money can move extremely quickly once investors believe a company has crossed an important technical or regulatory threshold. Getting to that threshold appears to matter more now.

What does a Longevity Biotech company need to show to raise a big round now?

A Longevity Biotech company increasingly needs to show that its science can survive contact with real drug development.

The largest current rounds are attached to concrete next steps. NewLimit is preparing for human trials and scaling manufacturing. Life Biosciences is funding a Phase 1 program. Loyal is financing regulatory work and commercial readiness. Juvena is advancing regenerative biologics toward development.

Even smaller financings point in the same direction. TECregen's $12.6 million seed is intended to move thymus-regeneration biologics toward clinical development. Rejuvenate Bio combined its $6 million round with a strategic research program with Merck Animal Health. HexemBio's investor rationale centers on proving its blood stem-cell rejuvenation approach in patients.

We cannot assign a clean milestone to every transaction because companies disclose different levels of detail. Still, the large-round pattern is quite clear: a promising aging mechanism alone is less compelling than a program with a believable path into trials, regulation or commercial use.

Are pharma and strategic investors becoming more important in Longevity Biotech?

Strategic investors are playing a somewhat bigger role in Longevity Biotech, and their involvement is increasingly tied to actual development programs.

Strategic-backed deals rose from 21.4% to 27.8% of financings. The increase itself is modest. The company examples are more interesting.

Eli Lilly backed NewLimit and has also been involved around Juvena's work. Merck Animal Health invested in Rejuvenate Bio alongside a formal R&D collaboration. Boehringer Ingelheim Venture Fund led TECregen's seed financing. XtalPi invested in Foundry BioSciences while also building a joint AI and automated experimental workflow with the company.

These relationships go beyond general exposure to longevity as an investment theme. Pharma and technology companies are increasingly showing up where they can contribute development infrastructure, drug-discovery capabilities or a potential route to market.

Is Longevity Biotech funding becoming more global?

Longevity Biotech activity is more geographically diverse now, but the money has become overwhelmingly North American.

Asia-Pacific went from zero transactions to four. Chinese companies Genturn Life and EonArk entered the dataset, and Singapore-based Gero raised $17 million. That gives the market a wider geographic pipeline than it had a year earlier.

Europe moved sharply in the other direction, from four deals to one. TECregen was the only current European financing we recorded.

North America's deal share barely changed, staying around 72%, yet its share of disclosed capital climbed to roughly 96%. NewLimit, Loyal and Life Biosciences explain most of that gap.

Geographic breadth has improved at the company level, especially through Asia, while large-round depth is currently concentrated in the United States.

Is Longevity Biotech becoming an old-company market?

Longevity Biotech is becoming more mature without becoming much older.

The median age of funded companies moved from roughly 4.7 years to 4.2 years, while the average remained just above five years. Companies did not suddenly need a decade of operating history before investors would fund them.

NewLimit was founded in 2021 and reached a $435 million Series C about five years later. Loyal, founded in 2019, raised $100 million. HexemBio, founded in 2024, returned to the market twice during 2026.

What has changed is how quickly some companies are moving from formation into expensive development stages. That is a more useful description of the current market than simply saying investors prefer older companies.

Are Longevity Biotech companies still raising to do research, or are they raising to scale?

The biggest Longevity Biotech rounds are increasingly paying for execution rather than open-ended experimentation.

NewLimit is funding clinical translation and manufacturing. Life Biosciences is running Phase 1. Loyal is working toward regulatory approval and launch readiness. Rejuvenate Bio has a strategic development collaboration. Junevity is trying to take its lead program into first-in-human studies.

Early-stage research still exists throughout the market. EonArk is building an AI longevity-discovery platform, General Control is working on multi-gene epigenetic medicines, and TECregen remains early in the development of its thymus-regeneration platform.

The difference is where the money piles up. Currently, the very large checks are going to companies with a defined product-development job to do.

What really changed in Longevity Biotech funding over the last 12 months?

Longevity Biotech has become a better funding market for proven companies and a tougher one for new entrants.

The biggest change is concentration. Disclosed capital more than doubled, yet removing rounds above $50 million leaves the market slightly below the previous period. NewLimit alone accounts for more than half of current funding.

Breadth improved far less than deal volume suggests. We recorded four additional financings but only one additional funded company, as several companies returned to the market more than once.

New-company creation weakened at the financing stage. Reliable first financings fell sharply, while follow-ons now make up close to nine out of ten audited transactions.

Cellular reprogramming is the clearest category winner. It gained deals, dollars and clinical relevance at the same time, although NewLimit still accounts for a huge part of the increase.

Investor behavior also looks more demanding. The companies receiving the largest checks currently tend to have clinical, regulatory, manufacturing or commercialization work directly ahead of them.

The biggest mistake would be to look at the 106% increase in disclosed capital and conclude that Longevity Biotech funding conditions simply doubled in strength. What changed is much more specific: the market can now finance a few validated longevity companies at serious biotech scale, while ordinary rounds remain modest and the flow of newly funded startups has weakened.